BOSTON and NEW YORK, December 15, 2020: Morgan Lewis represented EmendoBio Inc., a next-generation novel nuclease discovery and gene editing technology company valued at $250 million, in the acquisition by AnGes Inc. EmendoBio is now an independent, wholly owned subsidiary of AnGes, a commercial-stage Japanese biopharmaceutical company focused on gene-based medicines.
Morgan Lewis partner Michael Barron and associate Brittney Wozniak represented EmendoBio.